This interim guidance is based on what is currently known about 2019 novel coronavirus (2019-nCoV) and transmission of other viral respiratory infections.
core
Human mobility restrictions and the spread of the Novel Coronavirus (2019-nCoV) in China
, 2020 Hanming Fang, Long Wang, Yang Yang
openalex +2 more sources
Dynamical analysis and numerical assessment of the 2019-nCoV virus transmission with optimal control. [PDF]
Sci RepLi S +4 more
europepmc +1 more source
Comprehensive update on current outbreak of novel coronavirus infection (2019-nCoV) [PDF]
, 2020 Kamal Kant Sahu +2 more
openalex +1 more source
2019-nCoV situation summary 2019 novel coronavirus (2019-nCoV) in the U.S : updated February 3, 2020
This is an emerging, rapidly evolving situation and CDC will provide updated information as it becomes available, in addition to updated guidance.Updated February 3, 2020CDC is closely monitoring an outbreak of respiratory illness caused by a novel (new)
core
Antiviral drugs suppress infection of 2019-nCoV spike pseudotyped virus by interacting with ACE2 protein. [PDF]
J Biochem Mol Toxicol, 2022 Wang J +6 more
europepmc +1 more source
Epidemic Prediction of 2019-nCoV in Hubei Province and Comparison with SARS in Guangdong Province [PDF]
, 2020 Yuxiao Bai
openalex
Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV). [PDF]
Biosensors (Basel), 2022 Zhang X +10 more
europepmc +1 more source
Brief report of the first cured 2019-nCoV pneumonia patient in West China Hospital [PDF]
, 2020 En‐Qiang Chen +10 more
openalex +1 more source